Illumina has long been treated as the genomic sequencing bellwether that can justify a premium multiple. Q3 2026 earnings told a different story than the share price did. The stock dropped about 19% to roughly US$236 in the first session after the release, even as management lifted full year revenue, margin and earnings guidance.

The real hinge of this quarter was profitability. Non GAAP operating margin reached 25% and free cash flow hit US$378 million, which is a powerful contrast to a market that suddenly priced the stock as if the thesis had cracked.

Love Illumina’s 25% non GAAP operating margin and US$378 million in free cash flow but uneasy about paying up after a sharp price move? You can compare it with a curated list of…